XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC.
about
New perspectives in glioblastoma antiangiogenic therapyAXL kinase as a novel target for cancer therapyOckham's razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancerClinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selectionEGFR-TKI resistance in NSCLC patients: mechanisms and strategiesMultiplexed quantum dot labeling of activated c-Met signaling in castration-resistant human prostate cancerExperimental approaches for the treatment of malignant gliomas.Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumorsSynthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapyLeveraging metabolomics to assess the next generation of temozolomide-based therapeutic approaches for glioblastomasThe challenges and the promise of molecular targeted therapy in malignant gliomas.New therapies for dedifferentiated papillary thyroid cancerImproved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?Resistance to the c-Met inhibitor KRC-108 induces the epithelial transition of gastric cancer cellsEpigenetic Silencing of SPINT2 Promotes Cancer Cell Motility via HGF-MET Pathway Activation in MelanomaForetinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling.A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma.Complex oncogenic signaling networks regulate brain tumor-initiating cells and their progenies: pivotal roles of wild-type EGFR, EGFRvIII mutant and hedgehog cascades and novel multitargeted therapies.Wnt/β-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells.Ionizing radiation in glioblastoma initiating cells.An update in the use of antibodies to treat glioblastoma multiforme.Cabozantinib for the treatment of kidney cancer.Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma.Personalization of targeted therapy in advanced thyroid cancer.Combined modality approaches in the management of adult glioblastoma.Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody
P2860
Q26746028-8263BB9B-0147-4694-898A-261D9CE3F5CCQ26863442-AF2068F9-91D9-4339-B196-662F10EA42A5Q28067777-9A2314CD-4B34-4F18-AF92-F8A1B8FD4142Q28074834-100873F1-00FA-41AA-8EE4-F1E066D52B5EQ28394310-CCFD85CE-BE17-46AB-AF43-02A3F297A8C6Q28478514-D58C1FE2-F21C-4C9D-A44F-0D1DD7C54DD9Q34127138-61131057-F783-41B9-A4E9-B38843C5335AQ35053276-D10E499F-AC8B-4C6D-A7E6-FA786FE98D4EQ35129076-84D6D854-E09C-49B3-950D-AD2FE01D2423Q35171890-80F9CD99-80D2-44B3-BD62-9A12BF08C361Q35214534-E9333B21-E136-4587-9121-5E04BC9068E6Q35381593-4932B611-3A7B-42D1-88AA-7D32052E583EQ35896530-0E72E225-777F-452A-8E43-BC495B75B4A0Q35928137-60DDB701-8026-4A5F-B557-93458A04335CQ35956303-815004F1-5559-46FA-A0ED-F767AC06339CQ36020888-F81C477A-F638-41B1-9D43-781CBD6B02CEQ36103026-051AE933-E3C4-457C-A397-99E2B2133D49Q36156854-0505DA0A-127D-4FC4-B15B-EE40450F2F45Q36280796-7D49A8E1-A8C6-4241-9AE3-E561E4026E38Q36544112-5F3623FC-BC5D-4CC5-B29F-99C1D60D83F1Q36746959-41F97D1B-969E-42EF-8609-89C0ED7696D1Q37329927-894AC280-0DAE-4CDC-9691-D1E9E5FE0C1FQ38668871-7AE4C8BB-64CC-4C63-8A24-BFAFDFD6E33DQ38835745-2BB60D9D-A90B-4C3E-94BD-27F2552E5EC0Q39428273-8B9E4745-7280-4E8B-A55D-474297CAA52DQ40922523-09B5ED17-2DC9-4AA5-811D-9282EE32D728Q42151501-4C8CC071-710A-4094-9F8A-5AE68FBCA8C7Q47940756-D650522E-36FC-4E69-825B-34446BA2B57EQ58748732-59A7669E-5A17-43AD-9E29-87A8C30D28D1
P2860
XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
XL-184, a MET, VEGFR-2 and RET ...... blastoma multiforme and NSCLC.
@ast
XL-184, a MET, VEGFR-2 and RET ...... blastoma multiforme and NSCLC.
@en
type
label
XL-184, a MET, VEGFR-2 and RET ...... blastoma multiforme and NSCLC.
@ast
XL-184, a MET, VEGFR-2 and RET ...... blastoma multiforme and NSCLC.
@en
prefLabel
XL-184, a MET, VEGFR-2 and RET ...... blastoma multiforme and NSCLC.
@ast
XL-184, a MET, VEGFR-2 and RET ...... blastoma multiforme and NSCLC.
@en
P2093
P2860
P1476
XL-184, a MET, VEGFR-2 and RET ...... oblastoma multiforme and NSCLC
@en
P2093
Alex Kofman
David Schiff
Fadila Guessous
Roger Abounader
Ying Zhang
P2860
P304
P577
2010-02-01T00:00:00Z